Yasmin

Yasmin is a brand name of drospirenone/ethinyl estradiol, approved by the FDA in the following formulation(s):

YASMIN (drospirenone; ethinyl estradiol - tablet; oral-28)

• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: May 11, 2001
  
  Strength(s): 3MG;0.03MG ^[RLD][AB]

Has a generic version of Yasmin been approved?

A generic version of Yasmin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Yasmin and have been approved by the FDA:

DROSPIRENONE AND ETHINYL ESTRADIOL (drospirenone; ethinyl estradiol tablet; oral-28)

• 
  Manufacturer: BARR
  
  Approval date: May 9, 2008
  
  Strength(s): 3MG;0.03MG ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: September 7, 2010
  
  Strength(s): 3MG;0.03MG ^[AB]

SYEDA (drospirenone; ethinyl estradiol tablet; oral-28)

• 
  Manufacturer: SANDOZ
  
  Approval date: March 28, 2011
  
  Strength(s): 3MG;0.03MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Yasmin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Dihydrospirorenone as an antiandrogen
  Patent 5,569,652
  Issued: October 29, 1996
  Inventor(s): Beier; Sybille & Elger; Walter & Nishino; Yukishige & Wiechert; Rudolf
  Assignee(s): Schering Aktiengesellschaft
  Dihydrospirorenone, ##STR1## preferably together with an estrogen, can be used for the production of a pharmaceutical agent suitable for treatment of hormonal irregularities during premenopause (menstruation stabilization), for hormonal substitution therapy during menopause, for treatment of androgen-induced disorders and/or for contraception.
  
  Patent expiration dates:
  
  
  • October 29, 2013
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY
  
  



• 
  Pharmaceutical composition for use as a contraceptive
  Patent 6,787,531
  Issued: September 7, 2004
  Inventor(s): Juergen; Hilman & Wolfgang; Heil & Ralph; Lipp & Renate; Heithecker & Michael; Huempel & Johannes W.; Tack
  Assignee(s): Schering AG
  A pharmaceutical composition comprises, as a first active agent, 6&bgr;,7&bgr;;15&bgr;,16&bgr;-dimethylene-3-oxo-17&agr;-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17&agr;-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.
  
  Patent expiration dates:
  
  
  • August 31, 2020
    
    ✓ 
    Drug product
  
  



• 
  PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDR
  Patent 6,933,395
  Issued: August 23, 2005
  Inventor(s): Mohr; Jörg-Thorsten & Nickisch; Klaus
  Assignee(s): Schering AG
  Process for the production of drospirenone (6β,7β; 15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, DRSP) (1) and 7α-(3-hydroxy-1-propyl)-6β,7β; 15β,16β-dimethylene-5β-androstane-3β,5,17β-triol (ZK 92836) and 6β,7β; 15β,16β-dimethylene-5β-hydroxy-3-oxo-17α-androstane-21,17-carbolactone (ZK 90965) as intermediate products of the process.
  
  Patent expiration dates:
  
  
  • August 11, 2017
    
    ✓ 
    Drug substance
  
  

See also...

• Yasmin Consumer Information (Drugs.com)
• Yasmin Consumer Information (Wolters Kluwer)
• Yasmin Consumer Information (Cerner Multum)
• Yasmin Advanced Consumer Information (Micromedex)
• Drospirenone/Ethinyl Estradiol Consumer Information (Wolters Kluwer)
• Drospirenone and ethinyl estradiol Consumer Information (Cerner Multum)
• Yaz 28 Advanced Consumer Information (Micromedex)
• Drospirenone and ethinyl estradiol Advanced Consumer Information (Micromedex)